Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids
Open Access
- 18 October 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10), e77963
- https://doi.org/10.1371/journal.pone.0077963
Abstract
Circulating nucleic acids (CNAs) are under investigation as a liquid biopsy in cancer. However there is wide variation in blood processing and methods for isolation of circulating free DNA (cfDNA) and microRNAs (miRNAs). Here we compare the extraction efficiency and reproducibility of 4 commercially available kits for cfDNA and 3 for miRNA using spike-in of reference templates. We also compare the effects of increasing time between venepuncture and centrifugation and differential centrifugation force on recovery of CNAs. cfDNA was quantified by TaqMan qPCR and targeted deep sequencing. miRNA profiles were assessed with TaqMan low-density arrays and assays. The QIAamp® DNA Blood Mini and Circulating nucleic acid kits gave the highest recovery of cfDNA and efficient recovery (>90%) of a 564bp spike-in. Moreover, targeted sequencing revealed overlapping cfDNA profiles and variant depth, including detection of HER2 gene amplification, using the Ion AmpliSeq™Cancer Hotspot Panel v2. Highest yields of miRNA and the synthetic Arabidopsis thaliana miR-159a spike-in were obtained using the miRNeasy Serum/Plasma kit, with saturation above 200 µl of plasma. miRNA profiles showed significant variation with increasing time before centrifugation (p<0.001) and increasing centrifugation force, with depletion of platelet associated miRNAs, whereas cfDNA was unaffected. However, sample replicates showed excellent reproducibility on TaqMan low density arrays (ρ = 0.96, p 12 years, highlighting the potential for analysis of stored sample biobanks. In the era of the liquid biopsy, standardisation of methods is required to minimise variation, particularly for miRNA.This publication has 31 references indexed in Scilit:
- Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker LevelsPLOS ONE, 2013
- LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survivalBMC Cancer, 2012
- Plasma Components Affect Accuracy of Circulating Cancer-Related MicroRNA QuantitationThe Journal of Molecular Diagnostics, 2012
- High resolution of microRNA signatures in human whole salivaArchives of Oral Biology, 2011
- Genomic analysis of circulating cell-free DNA infers breast cancer dormancyGenome Research, 2011
- Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAsBMC Genomics, 2011
- Plasma microRNAs as potential biomarkers for non-small-cell lung cancerLaboratory Investigation, 2011
- Detection of HER2 amplification in circulating free DNA in patients with breast cancerBritish Journal of Cancer, 2011
- miRBase: integrating microRNA annotation and deep-sequencing dataNucleic Acids Research, 2010
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008